The MedTech company NeoDynamics AB (publ), currently listed on Spotlight Stock Market, has received a conditional approval for admission to trading on Nasdaq First North Growth Market in Stockholm. The first day for trading on Nasdaq First North is May 2, 2022, and the last day on trading on Spotlight Stock Market is April 29, 2022. Shareholders in NeoDynamics will not have to take any action in connection with the list change.
NeoDynamics has prepared a Supplementary Document which will be published on the company’s website on April 28. The Prospectus published March 4, 2022 and the Supplementary Document constitutes the Company Description. The Supplementary Document has only been prepared in connection with the application for admission to trading the shares on Nasdaq First North and does not contain any offer to the public to subscribe or otherwise acquire shares or other financial instruments in the Company, either in Sweden or in any other jurisdiction. The remaining conditions for approval are customary.
NeoDynamics shares will continue to be traded under the short name NEOD on Nasdaq First North.
Redeye AB has been appointed the Company's Certified Adviser on Nasdaq First North.
For further information, please contact:
CEO Anna Eriksrud, phone +46 708 444 966 or e-mail email@example.com
CFO Aaron Wong, e-mail firstname.lastname@example.org
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients.
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.